Loading
NASDAQHealthcareMedical - Specialties
Latest quote
$19.715
+$0.485 · +2.52%
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
Regular session
$19.715
+$0.485 · +2.52%
Regular session · ET · Market data may be delayed.
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
Day range
Current $19.715
52-week range
Current $19.715
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
48
Fair Value
Sentiment
66
Bullish
Risk
26
Moderate Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
Day range
Current $19.715
52-week range
Current $19.715
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 112.82M USD | 119.91M USD | 120.79M USD | 113.83M USD | 147.79M USD |
| Cost of goods sold | 49.01M USD | 43.91M USD | 38.26M USD | 40.61M USD | 64.85M USD |
| Gross profit | 63.81M USD | 76M USD | 82.53M USD | 73.22M USD | 82.94M USD |
| Research and development | 25.77M USD | 25.54M USD | 21.76M USD | 18.32M USD | 27.33M USD |
| Selling, general, and administrative | 49.09M USD | 55.56M USD | 59.93M USD | 51.23M USD | 74.1M USD |
| Operating expenses | 74.86M USD | 81.1M USD | 81.69M USD | 69.55M USD | 80.33M USD |
| Interest income | — | — | 2.31M USD | 654K USD | — |
| Depreciation and amortization | 5.73M USD | 8.12M USD | 14.22M USD | 14.49M USD | 14.32M USD |
| Operating income | −11.05M USD | −5.1M USD | 844K USD | 3.67M USD | 2.62M USD |
| Net income | −10.88M USD | −56.39M USD | −82.67M USD | −14.86M USD | 4.13M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$21.00
6.52% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI8.3M0.00%2.3T USD0.03%$381.37+0.48%
iShares Russell 2000 ETFIWM5.88M0.01%77.7B USD0.19%$278.76+0.43%
Vanguard Extended Market ETFVXF3.26M0.00%95.4B USD0.05%$234.66+0.66%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV2.97M0.01%26.91B USD0.33%$38.065-0.09%
iShares Russell 2000 Value ETFIWN2.14M0.02%13.75B USD0.24%$211.19+0.11%
Fidelity Small-Mid Multifactor ETFFSMD2.08M0.08%2.49B USD0.15%$50.03+0.62%
Dimensional - US Small Cap ETFDFAS2M0.01%33.8B USD0.31%$78.375+0.35%
Vanguard Russell 2000 ETFVTWO1.38M0.01%18B USD0.06%$112.6+0.45%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFU.S. Small Cap Value Portfolio ETF Class SharesDFSViShares Russell 2000 Value ETFIWNFidelity Small-Mid Multifactor ETFFSMDDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
